

Rebecca A Harrison

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5119411/publications.pdf>

Version: 2024-02-01

35
papers

787
citations

686830

13
h-index

552369

26
g-index

35
all docs

35
docs citations

35
times ranked

1103
citing authors

#	ARTICLE	IF	CITATIONS
1	Post Stroke Pain: Identification, Assessment, and Therapy. <i>Cerebrovascular Diseases</i> , 2015, 39, 190-201.	0.8	290
2	SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. <i>Neuro-Oncology</i> , 2021, 23, 1835-1844.	0.6	64
3	Measuring Self-Reported Cancer-Related Cognitive Impairment: Recommendations From the Cancer Neuroscience Initiative Working Group. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1625-1633.	3.0	46
4	Ventral hippocampal involvement in temporal order, but not recognition, memory for spatial information. <i>Hippocampus</i> , 2008, 18, 251-257.	0.9	37
5	A Naturalistic Study of Predictors and Risks of Atypical Antipsychotic Use in an Attention-Deficit/Hyperactivity Disorder Clinic. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2009, 19, 575-582.	0.7	33
6	Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial. <i>Clinical Cancer Research</i> , 2020, 26, 3565-3577.	3.2	30
7	A Narrative Review of Persistent Post-Stroke Headache – A New Entry in the International Classification of Headache Disorders, 3rd Edition. <i>Headache</i> , 2018, 58, 1442-1453.	1.8	24
8	Cortical Brain Age from Pre-treatment to Post-chemotherapy in Patients with Breast Cancer. <i>Neurotoxicity Research</i> , 2020, 37, 788-799.	1.3	22
9	Overlapping autoimmune syndrome: A case of concomitant anti-NMDAR encephalitis and myelin oligodendrocyte glycoprotein (MOG) antibody disease. <i>Journal of Neuroimmunology</i> , 2020, 339, 577124.	1.1	21
10	Intracranial dural, calvarial, and skull base metastases. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 149, 205-225.	1.0	20
11	Nitrous Oxide (N ₂ O)-Induced Acute Psychosis. <i>Canadian Journal of Neurological Sciences</i> , 2014, 41, 672-674.	0.3	17
12	Neurologic Toxicities of Cancer Immunotherapies: a Review. <i>Current Neurology and Neuroscience Reports</i> , 2020, 20, 27.	2.0	17
13	Neurocognitive Function in Adult Cancer Patients. <i>Neurologic Clinics</i> , 2018, 36, 653-674.	0.8	15
14	Clinical trial participation of patients with glioblastoma at The University of Texas MD Anderson Cancer Center. <i>European Journal of Cancer</i> , 2019, 112, 83-93.	1.3	15
15	Functional connectome biotypes of chemotherapy-related cognitive impairment. <i>Journal of Cancer Survivorship</i> , 2020, 14, 483-493.	1.5	15
16	A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma. <i>CNS Oncology</i> , 2022, 11, CNS87.	1.2	15
17	Pre-surgical connectome features predict IDH status in diffuse gliomas. <i>Oncotarget</i> , 2019, 10, 6484-6493.	0.8	14
18	Neurocognitive dysfunction in adult cerebellar medulloblastoma. <i>Psycho-Oncology</i> , 2019, 28, 131-138.	1.0	12

#	ARTICLE	IF	CITATIONS
19	Treatment of Glioblastoma in the Elderly. <i>Drugs and Aging</i> , 2018, 35, 707-718.	1.3	11
20	Neurocognitive Impairment After Hematopoietic Stem Cell Transplant for Hematologic Malignancies: Phenotype and Mechanisms. <i>Oncologist</i> , 2021, 26, e2021-e2033.	1.9	11
21	Predicting Patient Reported Outcomes of Cognitive Function Using Connectome-Based Predictive Modeling in Breast Cancer. <i>Brain Topography</i> , 2020, 33, 135-142.	0.8	10
22	Aggressiveness of care at end of life in patients with high-grade glioma. <i>Cancer Medicine</i> , 2021, 10, 8387-8394.	1.3	9
23	The association of genetic polymorphisms with neuroconnectivity in breast cancer patients. <i>Scientific Reports</i> , 2021, 11, 6169.	1.6	8
24	Single-agent ONC201 in recurrent H3 K27M-mutant diffuse midline glioma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3615-3615.	0.8	8
25	Phase I/II study to evaluate the safety and clinical efficacy of atezolizumab (atezo; aPDL1) in combination with temozolomide (TMZ) and radiation in patients with newly diagnosed glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2020, 38, 2511-2511.	0.8	7
26	Cell Signaling Pathways in Brain Tumors. <i>Topics in Magnetic Resonance Imaging</i> , 2017, 26, 15-26.	0.7	5
27	Pearls & Oysters: Primary Pineal Melanoma With Leptomeningeal Carcinomatosis. <i>Neurology</i> , 2021, 97, 248-250.	1.5	4
28	A phase I/II clinical trial of autologous CMV-specific T cells in glioblastoma (GBM) patients to reveal a lack of immune effector function.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2515-2515.	0.8	2
29	Clinical efficacy of ONC201 in thalamic H3 K27M-mutant glioma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3617-3617.	0.8	2
30	Neurologic Toxicities of Immunotherapy. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 417-429.	0.8	2
31	RARE-63. MULTICENTRIC GLIOMA IN OLLIER DISEASE: A CASE REPORT AND REVIEW OF THE LITERATURE. <i>Neuro-Oncology</i> , 2016, 18, vi172-vi172.	0.6	1
32	NCOG-17. EVALUATION OF NEUROCOGNITIVE FUNCTION IN PATIENTS WITH CEREBELLAR MEDULLOBLASTOMA. <i>Neuro-Oncology</i> , 2016, 18, vi123-vi123.	0.6	0
33	Patterns of care for pediatric patients with newly-diagnosed grade II gliomas. <i>Child's Nervous System</i> , 2021, 37, 1563-1572.	0.6	0
34	A phase 1/2 study of selinexor in combination with standard of care therapy for newly diagnosed or recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS2071-TPS2071.	0.8	0
35	First Case of Association between Autoimmune Autonomic Ganglionopathy (AAG) and Myeloproliferative Neoplasms (MPNs). <i>Blood</i> , 2021, 138, 4629-4629.	0.6	0